Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP.
about
Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptorVPAC receptors: structure, molecular pharmacology and interaction with accessory proteinsTransmembrane signal transduction by peptide hormones via family B G protein-coupled receptorsN-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinantsIdentification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptideAgnathan VIP, PACAP and their receptors: ancestral origins of today's highly diversified formsThe human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20Cloning and functional characterization of the human VIP1/PACAP receptor promoter.Black widow spider alpha-latrotoxin: a presynaptic neurotoxin that shares structural homology with the glucagon-like peptide-1 family of insulin secretagogic hormones.Insulinotropic toxins as molecular probes for analysis of glucagon-likepeptide-1 receptor-mediated signal transduction in pancreatic beta-cells.Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation.Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling.The VPAC1 receptor: structure and function of a class B GPCR prototype.Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptorsPTHR1 mutations associated with Ollier disease result in receptor loss of function.Exploration of the endogenous agonist mechanism for activation of secretin and VPAC1 receptors using synthetic glycosylated peptidesVasoactive intestinal polypeptide type-1 receptor regulation. Desensitization, phosphorylation, and sequestration.Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide.Domains determining agonist selectivity in chimaeric VIP2 (VPAC2)/PACAP (PAC1) receptorsThe human VPAC1 receptor: three-dimensional model and mutagenesis of the N-terminal domain.Identification of a VIP-specific receptor in guinea pig tenia coli.Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor.Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP.Distinct structural and functional roles of conserved residues in the first extracellular domain of receptors for corticotropin-releasing factor and related G-protein-coupled receptors.Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling.Shark rectal gland vasoactive intestinal peptide receptor: cloning, functional expression, and regulation of CFTR chloride channels.
P2860
Q24328795-F11F7BC9-C6E8-43D5-B2DE-B380E1A53868Q26827172-EB37F61C-F194-41ED-B8E2-69346F642FE1Q28082755-81CBB5E8-6405-4058-B59A-3F3F97EBBC73Q28139403-6A00579C-9BC1-4E43-91D1-C044B1448733Q28143861-6A08D84E-19CF-4EEF-ADCA-45096A2711F1Q28728067-06BF88B5-5EAF-4C33-8E18-51C8C69D9505Q30859120-41A3C898-BBEC-4F29-BC48-50FFFA830A52Q31917596-13B35D2F-52E7-486A-B11E-F6F17C3FF4D2Q34074706-F6265108-05D3-49AE-9000-BF60D76FC54FQ34086426-949B8E13-3B86-44C8-ACA2-E7489576DCB2Q34388733-1EF836FB-5F2D-496B-842F-4834BA6DFB54Q34963202-F7FF6775-7BE5-4E74-9050-62AE5B6061A3Q36403782-B3BF2853-5A83-4951-9D61-36427BB78957Q36710162-2A3FE63A-DEB0-4260-B1F9-9E8D00914C2BQ37294776-4CD45FA0-EB88-44A8-9F9C-0BB773B7D539Q37417464-E86AF8A8-9324-4DCA-8FCE-B82BAF06B1BEQ40735531-1E8254DC-F522-49FA-8058-2906E4D41912Q41197334-B86E1019-D086-4866-852E-38ACF4A7A2E3Q42172879-0F572EFA-0AC7-44F0-A28D-765D4CC460F7Q43513186-1C48BBA9-08F8-4923-8188-156F9B54B3AFQ43717006-89389AB8-D5C0-424D-9A5E-7795B84CF542Q44478818-243B32E0-B651-4279-93CB-5CAED72EB11EQ44973271-73C157BD-3D73-4C22-8F6F-A5141ECCF97BQ46947611-FA4CD799-D073-4615-BCB5-63A6A8385842Q46977928-82E05417-427F-40DA-84F7-67FF858E1AC7Q48521517-474D6D63-CF1F-482F-9938-AF27D4F7030F
P2860
Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Highly conserved aspartate 68, ...... l for its ability to bind VIP.
@ast
Highly conserved aspartate 68, ...... l for its ability to bind VIP.
@en
Highly conserved aspartate 68, ...... l for its ability to bind VIP.
@nl
type
label
Highly conserved aspartate 68, ...... l for its ability to bind VIP.
@ast
Highly conserved aspartate 68, ...... l for its ability to bind VIP.
@en
Highly conserved aspartate 68, ...... l for its ability to bind VIP.
@nl
prefLabel
Highly conserved aspartate 68, ...... l for its ability to bind VIP.
@ast
Highly conserved aspartate 68, ...... l for its ability to bind VIP.
@en
Highly conserved aspartate 68, ...... l for its ability to bind VIP.
@nl
P2093
P356
P1476
Highly conserved aspartate 68, ...... l for its ability to bind VIP.
@en
P2093
Couvineau A
Laburthe M
Rouyer-Fessard C
P304
P356
10.1006/BBRC.1995.1034
P407
P577
1995-01-01T00:00:00Z